SOPH

SOPHiA GENETICS SA

$7.86

4.94%
SectorHealthcareIndustryHealth Information ServicesCountrySwitzerland

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Source: Yahoo Finance
AI summary

Price & performance

1M-13.6%
3M+1.9%
YTD+49.3%
1Y+48.9%
52-week range—
Beta1.01
Full chart and returns against a benchmark

Q-Score

49/ 100

Quality against peers; 50 is the peer median.

Growth66
Risk59
Performance65
Valuation35
Profitability38
Leverage34
Sentiment39
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$77.3M+18.6%
Net income-$79M
Net margin-102.2%-6.3 pts
Historical fundamentals

Revenue exposure

86%of revenue from outside the US
Other Countries In Europe, Middle East, And Africa33%
France15%
United States14%
Regions, segments, customers and suppliers

Valuation

SOPHIndustryP/E—67.40P/S8.714.25EV/EBITDA—44.97P/B14.286.14PEG—0.25
Dividend yield0.00%
Every valuation metric

Earnings

Nov 3next report, before the open
EPS estimate$-0.20
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate